Shareholding disclosure

UBS Group AG

Declared position

8.03%

Threshold

Crossed upwards

Timeline

Published

19.01.2021

Transaction

08.01.2021

Voting rights breakdown

Voting rights acquired8.03%

Voting rights sold0.25%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAL1F00055

Beneficial owner

UBS Group AG

Declared address

UBS Group AG, Zürich

Crossing above 5% in voting rights (Section 4.1 & 4.3)

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

UBS Group AG

Basilea Pharmaceutica AG, Allschwil19.01.2021TAL1F00055

Disclosure summary

UBS Group AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the acquisition side, published by SIX Exchange Regulation on 19.01.2021, at 8.03% of voting rights. Notice category: Single shareholder.

Disclosed position

8.03%

Voting rights acquired

Voting rights acquired8.03%

Voting rights sold0.25%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

UBS Group AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 19.01.2021.

Publication date19.01.2021

Transaction date08.01.2021

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerUBS Group AG

Declared addressUBS Group AG, Zürich

CategorySingle shareholder

Voting rights acquired8.03%

Voting rights sold0.25%

Below threshold0%

ExchangeXSWX

Notification IDTAL1F00055

Commercial register

CHE-395.345.924

Registered

Zefix record

Conditions

Crossing above 5% in voting rights (Section 4.1 & 4.3)

Source: SIX Exchange Regulation · Publication date: 19.01.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open